Previous 10 | Next 10 |
TORONTO, ONTARIO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products,...
2023-08-09 14:48:51 ET Aeterna Zentaris press release ( NASDAQ: AEZS ): Q2 GAAP EPS of -$0.52. Revenue of $2.2M. Total revenue for the three-month period ended June 30, 2023 was $2.2 million as compared with ($0.2 million) for the same period in 2022, representing an i...
Ended the quarter with $42.2 million in cash, expected to fund operations into 2025 Driving patient recruitment for Phase 3 DETECT trial for the diagnosis of Childhood Onset Growth Hormone Deficiency TORONTO, ONTARIO, Aug. 09, 2023 (GLOBE NEWSWIRE) ...
Highlights progress, recent developments and upcoming key milestones C ompany c ontinu es to build growing body of data across pipeline , a dvancing towards first in human studies S trong financial position with cash projected to fund op...
Live moderated video webcast on Thursday, July 13 th at 10:00 AM ET TORONTO, ONTARIO, July 05, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company de...
TORONTO, ONTARIO, June 14, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that all ite...
TORONTO, ONTARIO, May 15, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, t...
2023-05-09 17:46:49 ET Aeterna Zentaris press release ( NASDAQ: AEZS ): Q1 GAAP EPS of -$0.88. Revenue of $2.1M (+40.0% Y/Y). The Company had $46.6 million in cash and cash equivalents at March 31, 2023. For further details see: Aeterna Zentaris GAAP EPS of -...
– Ended the quarter with $ 46 . 6 million in cash, expected to fund operations into 2025 – Continued efforts to accelerat e recruitment for DETECT trial A ctively seeking alternate development and commercializatio...
2023-04-05 08:48:13 ET The shares of nano-cap biotech Aeterna Zentaris ( NASDAQ: AEZS ) lost ~13% pre-market Wednesday after announcing a temporary halt to U.S. sales of its lead product Macrilen (macimorelin), effective May 23, 2023. The temporary move follows last year...
News, Short Squeeze, Breakout and More Instantly...
Aeterna Zentaris Inc. Company Name:
AEZS Stock Symbol:
NASDAQ Market:
Aeterna Zentaris Inc. Website:
2024-07-17 19:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
TORONTO, ONTARIO, July 16, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for he...
Aeterna Zentaris Inc. (NASDAQ: AEZS) is one of today's top gainers. The company's shares have moved 24.97% on the day to $6.7. Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimore...